Who holds the trilaciclib spirocyclic patent, and what does it cover?
Trilaciclib (brand name reported as Cosela) is a cancer drug whose intellectual property includes patents covering specific chemical structures, including “spirocyclic” forms. In general, “spirocyclic” patent protection targets the chemical scaffold and related composition claims for that scaffold, such as particular spirocyclic compounds, salts, solvates, and sometimes methods of use and manufacture tied to those compounds. The exact assignee(s), claim scope, and whether coverage is “compound-only” versus “formulation/method” depends on the specific patent family in force for the spirocyclic invention.
What is a “spirocyclic” patent in this context?
A spirocyclic patent claim protects a molecule that has a spiro-linked ring system (a structural feature where two rings share a single atom). For drug products like trilaciclib, spirocyclic claims typically matter because the protected scaffold can be the core of later “around-the-patent” attempts—competitors may try to use different ring systems, stereochemistry, or substituents to avoid infringement.
When does the trilaciclib spirocyclic patent expire?
Patent expiration depends on the priority date, the jurisdiction, and whether any extensions apply (for example, regulatory-related patent term adjustments). Without the specific patent number(s) for the trilaciclib spirocyclic family, the expiration date cannot be stated reliably. If you share the patent number or publication (e.g., US publication number, EP publication number, or the assignee name tied to the spirocyclic claims), the timeline can be pinned down to the correct country and docket.
Are there challenges to the trilaciclib spirocyclic patent (generic/biosimilar or litigation)?
Spiral ring and other core compound patents often become focal points in generic or biosimilar challenges. Common dispute paths include:
- Claim construction fights (what the claims actually cover).
- Non-infringement arguments (the competitor’s molecule differs in the spirocyclic scaffold or substituents).
- Invalidity arguments (prior art, obviousness, or lack of enablement).
The presence and outcome of any challenges again depends on which specific trilaciclib spirocyclic patent family you mean.
How do you identify the correct trilaciclib “spirocyclic” patent family?
To locate the right patents, you typically search by:
- The drug name (trilaciclib) plus “spiro” / “spirocyclic”
- The chemical name(s) of trilaciclib and related intermediates
- Assignee names tied to trilaciclib’s original discovery or commercialization
- Patent family links from a known core patent number
If you provide either the patent number, assignee, jurisdiction (US/EP/WO/JP, etc.), or a link to the patent record you’re looking at, I can tell you what that specific patent’s spirocyclic claims cover and how close competing compounds would likely need to differ.
What happens if a competitor makes a “near” spirocyclic structure?
Even small changes can matter. In spirocyclic patents, infringement risk usually hinges on whether the competitor’s compound matches the claimed spirocyclic structural elements (ring connections, shared atom, substitution pattern, stereochemistry) and whether it falls within claim definitions for salts/solvates or certain embodiments. If not, a competitor may argue non-infringement; if yes, they may face injunction risk unless the patent is invalidated or expired.
What side questions usually come up with trilaciclib spirocyclic patents?
People often look up:
- The exact claim language tied to the spirocyclic scaffold
- Whether the patent covers only the compound or also formulations and methods
- The jurisdiction-specific expiration date
- Whether the patent is part of a larger family that has multiple national filings
- Whether there are regulatory exclusivity periods that delay generic entry even if a patent expires
Quick next step
Share the specific patent number (or country + publication number) you mean by “trilaciclib spirocyclic patent,” and I’ll map:
- what it claims (spirocyclic scope),
- who owns it,
- and the expected expiration timeline for that jurisdiction.